DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
South Korea · Delayed Price · Currency is KRW 5,280.00
+220.00 (4.35%)
At close: Apr 1, 2026
DongKoo Bio & Pharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 50,272 | 2,036 | 11,812 | 6,614 | 9,327 |
Depreciation & Amortization | 8,919 | 7,274 | 6,028 | 5,632 | 5,054 |
Loss (Gain) From Sale of Assets | -3.63 | -5.98 | 0 | -123.89 | 1.33 |
Asset Writedown & Restructuring Costs | 4,721 | 665.56 | - | - | 0 |
Loss (Gain) From Sale of Investments | -52,191 | -7,119 | -2,077 | 8,869 | -1,090 |
Loss (Gain) on Equity Investments | -3,161 | 13,112 | 660.61 | -118.28 | 1,733 |
Stock-Based Compensation | 193.02 | 251.89 | 224.51 | - | - |
Provision & Write-off of Bad Debts | 159.22 | -193.35 | -52.82 | 40.44 | 241.76 |
Other Operating Activities | -2,379 | 2,295 | 1,697 | 331.91 | 638.04 |
Change in Accounts Receivable | -251.85 | 478.4 | -1,333 | -2,861 | 1,431 |
Change in Inventory | -5,950 | -6,632 | -12,838 | -6,686 | -1,897 |
Change in Accounts Payable | -10,287 | 4,389 | -3,093 | 2,715 | 2,399 |
Change in Other Net Operating Assets | 5,672 | 793.42 | 2,558 | 2,404 | 65.1 |
Operating Cash Flow | -4,287 | 17,344 | 3,585 | 16,819 | 17,903 |
Operating Cash Flow Growth | - | 383.75% | -78.68% | -6.05% | 139.06% |
Capital Expenditures | -17,656 | -21,866 | -13,845 | -4,978 | -4,266 |
Sale of Property, Plant & Equipment | 3.64 | 6 | 0.66 | 300.44 | 11.97 |
Sale (Purchase) of Intangibles | -2,796 | -3,598 | -2,034 | -6,098 | -1,137 |
Investment in Securities | -16,096 | -18,433 | 11,851 | -16,287 | 6,202 |
Other Investing Activities | -639.7 | 583.28 | -106 | 39 | -366.43 |
Investing Cash Flow | -38,927 | -45,033 | -5,133 | -27,014 | 463.93 |
Short-Term Debt Issued | 63,937 | 47,029 | 7,500 | 15,000 | 70.75 |
Long-Term Debt Issued | 22,578 | 9,895 | 1,447 | - | - |
Total Debt Issued | 86,515 | 56,924 | 8,947 | 15,000 | 70.75 |
Short-Term Debt Repaid | -42,436 | -13,528 | - | - | - |
Long-Term Debt Repaid | -1,733 | -935.5 | -1,126 | -5,966 | -742.12 |
Total Debt Repaid | -44,168 | -14,463 | -1,126 | -5,966 | -742.12 |
Net Debt Issued (Repaid) | 42,347 | 42,461 | 7,821 | 9,034 | -671.37 |
Repurchase of Common Stock | - | -3,408 | -79.9 | -2,995 | -1,998 |
Dividends Paid | -3,245 | -3,313 | -3,038 | -2,804 | -942.94 |
Other Financing Activities | 409.83 | 1,454 | 49 | -50 | -76.1 |
Financing Cash Flow | 39,512 | 37,194 | 4,752 | 3,185 | -3,688 |
Foreign Exchange Rate Adjustments | -109.02 | 154.83 | -4.74 | -33.91 | -2.27 |
Miscellaneous Cash Flow Adjustments | -0 | - | - | 0 | -0 |
Net Cash Flow | -3,812 | 9,660 | 3,199 | -7,043 | 14,676 |
Free Cash Flow | -21,944 | -4,522 | -10,260 | 11,841 | 13,637 |
Free Cash Flow Growth | - | - | - | -13.16% | 514.06% |
Free Cash Flow Margin | -9.04% | -1.81% | -4.76% | 6.07% | 8.79% |
Free Cash Flow Per Share | -781.76 | -166.62 | -371.44 | 426.63 | 482.57 |
Cash Interest Paid | 3,303 | 2,828 | 1,672 | 902.19 | 362.76 |
Cash Income Tax Paid | 4,301 | 2,775 | 4,104 | 3,076 | 1,392 |
Levered Free Cash Flow | -35,979 | -9,684 | -15,354 | -140.43 | 10,027 |
Unlevered Free Cash Flow | -33,786 | -7,875 | -14,254 | 509.14 | 10,286 |
Change in Working Capital | -10,817 | -970.91 | -14,706 | -4,427 | 1,999 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.